Drug–Microbiome Interactions: How Medications Reshape Microbial Communities and Study Design

For research use only. Not for use in diagnostic procedures.

A researcher planning a gut microbiome study will carefully control for diet, age, BMI, and perhaps smoking status. Medication use, by contrast, frequently goes unrecorded — or gets lumped into a single yes/no checkbox on a case report form. That checkbox hides a problem large enough to alter the conclusions of an entire study.

Non-antibiotic medications reshape the gut microbial community in ways that rival the effects of disease itself. A 2018 screen of more than 1,000 marketed drugs found that 24% of non-antibiotic compounds inhibited the growth of at least one gut bacterial strain in vitro [1]. A subsequent population-scale analysis of three independent cohorts showed that 41 drug categories were associated with shifts in microbial composition and metabolic function, with proton pump inhibitors, metformin, antibiotics, and laxatives producing the strongest associations after controlling for polypharmacy [2]. When these drug-driven shifts overlap with the microbial signatures a study is designed to detect, the result is not just noise — it can be systematic confounding that statistical adjustment alone cannot fully resolve.

This article offers a practical framework for researchers who need to account for medication effects when designing microbiome studies. It covers which drug classes matter most, how to decide whether drug effects are confounders or signals of interest, what metadata to collect, and the consequences of ignoring medications entirely.

Medication as the Overlooked Variable

Microbiome studies routinely collect metadata on host demographics and lifestyle. Medication history, despite its documented effect size, is treated with less rigor. One reason is historical: early microbiome research focused on antibiotics as the primary pharmaceutical disruptor, and the pervasive influence of non-antibiotic drugs took longer to recognize. Another is practical — polypharmacy is common, especially in aging and disease cohorts, making it difficult to isolate individual drug effects.

The scale of the problem became clear through large-cohort studies. In the Dutch LifeLines-DEEP cohort, researchers found that drug use explained more variance in gut microbiome composition than any other measured host factor except stool consistency [2]. A 2018 analysis of the TwinsUK cohort identified 19 drug categories with significant microbiome associations, including many that were overlooked in earlier work [3]. More recently, a 2025 study demonstrated that medications can exert carryover and additive effects on the gut microbiome — meaning the window of influence extends beyond the period of active use [4].

These findings carry a practical message. If a study enrolls participants with type 2 diabetes, the metformin effect on the gut microbiome may be larger than the disease effect itself. Forslund and colleagues showed that when metformin-treated and untreated individuals with type 2 diabetes were analyzed separately, the microbial signatures attributed to diabetes changed substantially — some "diabetes-associated" patterns were actually metformin-associated patterns [5]. Researchers studying any condition with high medication prevalence need to design for this reality from the start.

Drug Classes That Reshape the Microbiome

Not all medications affect the microbiome equally. The strongest and most consistent associations involve drugs that act on the gastrointestinal tract or that reach the gut lumen at pharmacologically relevant concentrations.

Proton pump inhibitors (PPIs) consistently rank among the most microbiome-disruptive drug classes. By raising gastric pH, PPIs remove a chemical barrier that normally limits oral and environmental bacteria from colonizing the lower gut. Cohort studies show that PPI users harbor increased abundances of oral Streptococcus species and Veillonella in stool samples, along with reduced microbial diversity [2, 6]. These shifts are large enough to confound case-control comparisons if PPI use is unevenly distributed between groups.

Metformin alters the gut microbiome through multiple mechanisms, including changes to bile acid metabolism, increased intestinal transit of Bacteroides species, and direct effects on microbial metabolic pathways. The metformin signature includes increased Escherichia-Shigella abundance, reduced Intestinibacter, and shifts in short-chain fatty acid production [5, 7]. Because metformin is the first-line treatment for type 2 diabetes, its microbiome effects are nearly impossible to disentangle from the disease without careful study design.

Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants have antimicrobial properties that were recognized in microbiology decades before their microbiome effects became a research focus. SSRIs inhibit the growth of several gut bacterial species at concentrations achievable in the intestinal lumen [1, 8]. The clinical significance of this antimicrobial activity in the context of depression research remains an active area of investigation.

Statins, NSAIDs, and laxatives each produce measurable microbiome shifts, though effect sizes vary by cohort and methodology. A comprehensive review by Weersma and colleagues catalogued the evidence for these and other drug classes, noting that the relationship is bidirectional — drugs alter the microbiome, and the microbiome in turn modifies drug pharmacokinetics through metabolism, bioactivation, and enterohepatic recirculation [6]. Understanding these bidirectional interactions sits at the center of drug target discovery efforts, where microbiome-derived insights increasingly inform compound selection and mechanism-of-action studies.

Figure 1: Major drug classes with documented effects on the gut microbiome, including the primary mechanisms through which they alter microbial community composition.

Confounder or Signal?

The decision to treat medication effects as a confounder or as a signal of interest depends on the research question. This distinction should be made before data collection begins.

When the goal is to identify microbial signatures of a disease, medication effects are confounders. If a study compares the gut microbiomes of individuals with and without depression, and the depression group has higher SSRI use, any microbial differences could reflect drug effects rather than disease biology. Simply matching groups on medication status or excluding medicated participants are common strategies, but they reduce sample size and generalizability.

When the goal is to understand drug-microbiome interactions themselves, medication effects become the signal. Pharmacomicrobiomics — the study of how the microbiome influences drug response — is a growing field that explicitly investigates these relationships [9]. In this context, detailed medication metadata, longitudinal sampling before and after drug initiation, and statistical models that account for polypharmacy are essential. For researchers building dedicated pharmacomicrobiomics programs, pharmaceutical microbiology solutions that pair taxonomic profiling with functional annotation can capture both the compositional and metabolic dimensions of drug-microbiome interactions.

Many studies fall somewhere between these two poles. A pragmatic approach is to collect rich medication metadata regardless of the primary research question, so that downstream analyses can test for drug effects even when they are not the original focus. A 2023 review in Signal Transduction and Targeted Therapy emphasized that treating medication as "background noise" without characterizing it is a missed opportunity that weakens reproducibility across the field [9].

Designing Around Medication Effects

No single study design eliminates medication confounding entirely, but several strategies substantially reduce its impact.

Stratify by medication class. Rather than using a binary "any medication" variable, categorize participants by the specific drug classes relevant to the study population. PPI users, metformin users, and SSRI users should be analyzed as distinct strata — or at minimum, their proportional representation should be balanced between comparison groups.

Use medication-adjusted models. Statistical approaches that incorporate medication as a covariate can reduce confounding, but they rely on the assumption that drug effects are additive and linear. For microbiome data, which is compositional and zero-inflated, specialized methods such as ANCOM-BC2 or MaAsLin 2 with medication variables included in the fixed-effects structure are more appropriate than simple linear models. For studies without dedicated in-house pipelines, microbial bioinformatics services can handle the specialized statistical frameworks required for medication-adjusted microbiome analysis. The key is to pre-specify which medication variables will be adjusted for, rather than exploring post hoc.

Collect pre- and post-medication samples where possible. Longitudinal designs that sample participants before and after drug initiation provide the strongest evidence for causal drug effects. In cohort studies where new medication starts are recorded, a within-subject comparison can distinguish drug-induced changes from pre-existing differences. Incorporating longitudinal gut microbiome sampling into study protocols — with consistent collection, preservation, and processing methods across time points — allows researchers to separate drug effects from stable inter-individual variation.

Exclude or match — but know what you lose. Excluding participants who take certain medications simplifies the analysis but reduces sample size and may introduce selection bias if the excluded group differs systematically from the included group. Propensity score matching on medication use can preserve sample size while improving balance, though it requires careful specification of the matching model.

Report medication use transparently. The Strengthening the Organization and Reporting of Microbiome Studies (STORMS) checklist recommends reporting medication use in microbiome studies, but compliance remains inconsistent [10]. At minimum, a supplementary table listing the number and proportion of participants taking each major drug class, stratified by comparison group, allows readers to assess potential confounding.

Figure 2: Decision framework for classifying medication effects as confounders or signals based on the research question, with recommended design strategies for each scenario.

Metadata Fields Worth Collecting

The quality of medication metadata determines whether drug effects can be accounted for in analysis. A single checkbox — "taking medications: yes/no" — provides almost no analytical value. Collecting the fields below transforms medication data from a yes/no flag into an analytically useful variable.

For studies where detailed medication histories are impractical, a minimum viable dataset includes drug class (not just drug name), duration category (<1 month, 1–12 months, >12 months), and timing of the most recent dose relative to sample collection. Even these three fields substantially improve the ability to test for medication effects in downstream analysis.

What Happens When Drugs Are Ignored

Studies that do not account for medication use risk three categories of error.

False positive associations. If a disease group has higher use of a microbiome-altering drug than the control group, microbial differences attributed to the disease may actually reflect the drug. This error is especially common in cross-sectional case-control studies where medication status is not reported.

Reduced reproducibility. Two studies of the same disease may reach different conclusions because their study populations had different medication profiles. Without transparent medication reporting, these discrepancies are difficult to diagnose and the literature accumulates contradictory findings.

Missed opportunities for discovery. Drug-microbiome interactions are themselves a source of biological insight. When medication data is not collected, the opportunity to detect these interactions — and to use them as covariates that strengthen rather than weaken a study's conclusions — is lost. Identifying consistent microbial signatures of drug exposure can also support microbial biomarker discovery, where drug-associated taxa or functional pathways serve as readouts of pharmacological modulation and potential efficacy predictors.

A 2025 study in mSystems that examined carryover and additive medication effects concluded that "medication represents a hidden confounder whose impact on microbiome study conclusions is likely underestimated" [4]. The authors recommended that medication use be treated as a core metadata variable, not an optional add-on.

Figure 3: Consequences of ignoring medication use in microbiome study design. When drug effects are unaccounted for, false positive associations, reduced reproducibility, and missed discovery opportunities become more likely.

A Planning Checklist for Your Next Study

Use this checklist during study design, before the first sample is collected.

• List the major drug classes expected in your study population based on the health conditions you are recruiting for.
• For each drug class, determine the expected direction and magnitude of microbiome effects using published literature.
• Decide whether drug effects will be treated as confounders, signals, or both — and document this decision.
• Collect medication metadata at the level of drug name, dose, duration, and timing relative to sampling.
• Pre-specify which medication variables will be included in your statistical model.
• Stratify or balance comparison groups on the most influential drug classes for your research question.
• Report medication use transparently in supplementary tables, broken down by comparison group.
• If excluding participants on certain medications, document the exclusion criteria and assess selection bias.
• Plan for polypharmacy — in older or disease cohorts, single-drug analysis may not capture the full exposure landscape.

Frequently Asked Questions

How many participants do I need to detect medication effects on the microbiome?

Statistical power depends on the drug class, the expected effect size, and the heterogeneity of the study population. For drug classes with large documented effects — PPIs and metformin, for example — effect sizes can be detected in cohorts of a few hundred participants, provided the medication variable is well-characterized and the comparison groups are balanced. For subtler drug effects or studies where polypharmacy is common, larger cohorts and multivariate models are needed. If medication effects are a primary endpoint, a formal power analysis using pilot data or published effect sizes is recommended.

Should I exclude all participants who take any medication?

Excluding all medication users is rarely the best approach. It reduces sample size, limits generalizability, and introduces selection bias — the people left in your study may not represent the population you intend to study. A more informative strategy is to collect detailed medication metadata and include drug class as a covariate in the analysis. If exclusion is necessary for a specific comparison, exclude only participants taking the drug classes most likely to confound that comparison, and report the exclusion criteria transparently.

What about antibiotics — are they in a category of their own?

Antibiotics exert the most dramatic and well-documented effects on the gut microbiome, and most microbiome studies already exclude participants with recent antibiotic use or treat antibiotic exposure as a separate covariate. The key message of recent research is that non-antibiotic drugs also produce meaningful effects. A study design that carefully controls for antibiotics but ignores PPIs or metformin may still be confounded. Antibiotic and non-antibiotic drug exposures should both be recorded.

How do I handle polypharmacy in my analysis?

Polypharmacy is common in aging populations and disease cohorts, and analyzing one drug at a time will miss additive or interactive effects. Approaches include grouping drugs by therapeutic class, using a "drug burden index" or similar composite score, and applying multivariate models that include multiple drug variables simultaneously. Machine learning methods such as random forest or gradient boosting can identify drug-microbiome associations in high-dimensional medication data, though they require larger sample sizes and careful validation.

Can the microbiome data itself reveal confounding by medications?

In some cases, yes. If a particular microbial species or functional pathway shows a strong association with a drug class that was not recorded during metadata collection, post hoc analysis of microbial signatures can flag potential unmeasured confounding. However, this approach is inherently circular — using the data to identify confounders risks overfitting and should be treated as hypothesis-generating rather than confirmatory. Collecting medication metadata prospectively remains the more reliable strategy.

References

1. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-628. doi:10.1038/nature25979
2. Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications. 2020;11(1):362. doi:10.1038/s41467-019-14177-z
3. Jackson MA, Verdi S, Maxan ME, et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nature Communications. 2018;9(1):2655. doi:10.1038/s41467-018-05184-7
4. Aasmets O, Taba N, Krigul KL, et al. A hidden confounder for microbiome studies: medications used years before sample collection. mSystems. 2025. doi:10.1128/msystems.00541-25
5. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-266. doi:10.1038/nature15766
6. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510-1519. doi:10.1136/gutjnl-2019-320204
7. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine. 2017;23(7):850-858. doi:10.1038/nm.4345
8. Cussotto S, Clarke G, Dinan TG, Cryan JF. Psychotropic drugs and the microbiome. Modern Trends in Psychiatry. 2021;32:113-133. doi:10.1159/000510423
9. Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug–microbiota interactions: an emerging priority for precision medicine. Signal Transduction and Targeted Therapy. 2023;8:386. doi:10.1038/s41392-023-01619-w
10. Mirzayi C, Renson A, Zohra F, et al. Reporting guidelines for human microbiome research: the STORMS checklist. Nature Medicine. 2021;27(11):1885-1892. doi:10.1038/s41591-021-01552-x